NCT02097004已完成4 期
Phase4, to Compare Efficacy and Safety of Therapeutic Vaccination With Intensified Schedule Plus Pegylated Interferon Dual Therapy on Seroclearance of HBS Antigen in Patients With Complete Virological Response Induced by Entecavir
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 111
- 试验地点
- 1
- 主要终点
- The rate of HBsAg-seroclearance
研究概览
简要总结
A randomized, Open label, Single center, Prospective study to compare efficacy and safety of Therapeutic Vaccination with Intensified schedule plus Pegylated Interferon dual Therapy on Seroclearance of Hepatitis B virus Surface Antigen in Patients with Complete Virological Response Induced by Entecavir
详细描述
A randomized, Open label, Single center, Prospective study to compare efficacy and safety of Therapeutic Vaccination with Intensified schedule plus Pegylated Interferon dual Therapy on Seroclearance of Hepatitis B virus Surface Antigen in Patients with Complete Virological Response Induced by Entecavir (E + VIP)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 20 and 75 year-old
- •HBsAg-positive for > 6 months apart (medical history can be alternative)
- •Currently being treated with entecavir 0.5 mg/day for more than 18 months
- •Undetectable HBV DNA in serum (<20IU/mL) and HBeAg-negative or positive for > 1year
- •HBsAg titer < 3,000 IU/mL
- •ALT<300 IU/L
- •Signed written informed consent after being instructed about the objective and procedure of the clinical study
排除标准
- •Patients with decompensated liver cirrhosis, any one of the following ① Serum bilirubin > 3 mg/dL
- •② Prothrombin time > 6 seconds prolonged or INR >2.3
- •③ Serum albumin < 2.8 g/dL
- •④ History of ascites, variceal hemorrhage, or hepatic encephalopathy
- •⑤ Child-Pugh score ≥7 (Child-Pugh class B or C)
- •Patients who have evidence of renal insufficiency defined as serum creatinine>1.5 mg/dL
- •Patients with psychological problem including depression
- •Patients who have previous/current significant co-morbidities including congestive heart failure, chronic kidney disease, hematologic disease and malignancy including hepatocellular carcinoma(patients with malignancy cured 5 years before screening can be enrolled)
- •Patients with seropositivity for anti-HCV, anti-HDV or anti-HIV
- •Patients who have excessive alcohol consumption (> 30 g/day)
- •Patients who have evidence of autoimmune hepatitis, hemochromatosis or Wilson's disease
- •Pregnant or breast feeding females or plan for pregnancy or no contraception
- •Patients with disease may deteriorate with interferon therapy(eg, autoimmune thyroiditis)
- •Patients who have an psoriasis
- •Patients who have history of antiviral-resistant HBV after previous treatment with oral antiviral agents
- •Previous diagnosis with immunodeficiency or concomitant treatment of immune suppressive agent or previous organ transplantation Recipients
- •Patients who have a history of hypersensitivity to study drug
- •Uncontrollable seizure, convulsion and/or central nervous system disorders
- •Patients with severe bone marrow disorder or with history of hypersensitivity to biologic agent such as vaccine.
- •Neutrophil count < 1,500/mm3 or platelet count < 75,000/mm3 or hemoglobin < 10 g/dl
- •Patients with Pulmonary disease (in case of history of pulmonary disease with complete recovery, enrollment is on investigator's discretion)
- •Patients who have a fever ≥ 38 °C at the baseline
- •Patients who have a risk of febrile response or systemic reaction
- •Patients who the investigator deems inappropriate to participate in this study
研究组 & 干预措施
Concomitant:Pegasys, Euvax B, Baracrude
Experimental
- Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks
- HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
- Continue Entecavir(0.5mg) for 100 weeks(once daily)
干预措施: Peginterferon alfa-2a (Biological)
Concomitant:Pegasys, Euvax B, Baracrude
Experimental
- Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks
- HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
- Continue Entecavir(0.5mg) for 100 weeks(once daily)
干预措施: HBV vaccination (Biological)
Concomitant:Pegasys, Euvax B, Baracrude
Experimental
- Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks
- HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
- Continue Entecavir(0.5mg) for 100 weeks(once daily)
干预措施: Entecavir (Drug)
Sequential:Pegasys, Euvax B, Baracrude
Experimental
- Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks
- HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks
- Continue Entecavir(0.5mg) for 100 weeks(once daily)
干预措施: Peginterferon alfa-2a (Biological)
Sequential:Pegasys, Euvax B, Baracrude
Experimental
- Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks
- HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks
- Continue Entecavir(0.5mg) for 100 weeks(once daily)
干预措施: HBV vaccination (Biological)
Sequential:Pegasys, Euvax B, Baracrude
Experimental
- Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks
- HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks
- Continue Entecavir(0.5mg) for 100 weeks(once daily)
干预措施: Entecavir (Drug)
Control Group
Active Comparator
- Continue Entecavir(0.5mg) for 100 weeks(once daily)
- After EOS(100W), injection(once weekly) a Peginterferon alfa-2a for 48 weeks
干预措施: Peginterferon alfa-2a (Biological)
Control Group
Active Comparator
- Continue Entecavir(0.5mg) for 100 weeks(once daily)
- After EOS(100W), injection(once weekly) a Peginterferon alfa-2a for 48 weeks
干预措施: Entecavir (Drug)
结局指标
主要结局
The rate of HBsAg-seroclearance
时间窗: The rate of HBsAg-seroclearance at the time point of at weeks 100
The rate of HBsAg-seroclearance at the time point of at weeks 100 in the sequential treatment group (24 weeks after termination of treatment) versus control group(ETV monotherapy) at weeks 100.
次要结局
- The rate of HBsAg-seroconversion(The rate of HBsAg-seroconversion at weeks 100)
- The change of HBsAg level from baseline(The change of HBsAg level from baseline at weeks 100)
- The change of HBsAg-seroclearance(The change of HBsAg-seroclearance at weeks 4, weeks 12, weeks 24, weeks 36, weeks 48, weeks 60, weeks 72, weeks 96, weeks 100, weeks 148)
- The change of HBsAg level(The change of HBsAg level at weeks 4, weeks 12, weeks 24, weeks 36, weeks 48, weeks 60, weeks 72, weeks 96, weeks 100, weeks 148)
- The change of HBsAg-seroconversion(The change of HBsAg-seroconversion at weeks 4, weeks 12, weeks 24, weeks 36, weeks 48, weeks 60, weeks 72, weeks 96, weeks 100, weeks 148)
研究者
Yoon Jun Kim
MD, PhD
Seoul National University Hospital
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary ObesityObesityNCT05821543Promomed, LLC240
已完成
3 期
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)Short Bowel SyndromeNCT02340819Shire11
已完成
4 期
Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in KoreaChronic Obstructive Pulmonary DiseaseNCT00864812The Korean Academy of Tuberculosis and Respiratory Diseases509
已完成
4 期
Safety, Tolerability, Pharmacokinetics and Efficacy of ARCOPlasmodium FalciparumMalaria, FalciparumNCT01930331Ifakara Health Institute60
已完成
4 期
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).Metastatic Colorectal CancerNCT03564938Bayer100